Please login to the form below

Not currently logged in
Email:
Password:

Genzyme in talks to foil sanofi-aventis bid

Genzyme has been courting several companies as possible alternatives to the proposed $18.5bn takeover by sanofi-aventis

Sanofi-aventis' (S-A) takeover target Genzyme has entered talks with several large pharma companies to scout a higher price than the French company's hostile $18.5bn ($69 per share) bid, according to knowledgeable sources quoted in British newspaper The Mail on Sunday.

Takeda, which is actively looking to expand in the US, was initially mentioned in connection with an $82 per share bid. However, the Wall Street Journal has reported that this is now unlikely to happen.  

Takeda and Genzyme have not commented on the reports. 

Informal takeover talks between Genzyme and S-A began in July, with S-A making a non-binding proposal of $18.5bn at the end of August. After Genzyme called the bid 'insufficient', the takeover attempt got hostile in early October, when S-A took its $69-per-share bid directly to Genzyme's shareholders. Earlier this month, S-A sent Genzyme a letter requesting that the biotech not take 'defensive measures' to derail the takeover. 

Other companies now reported to be in talks with Genzyme include GlaxoSmithKline, Eli Lilly, Johnson & Johnson and Pfizer. 

Genzyme has stated that it believes it will be able to obtain a price of $89 per share.

15th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics